本文選題：急性腦梗死 + MCAO模型��； 參考：《中華中醫(yī)藥雜志》2017年09期

【摘要】：目的:評價(jià)依達(dá)拉奉聯(lián)合疏血通注射液治療急性腦梗死大鼠的療效和安全性。方法:將SD大鼠隨機(jī)分為:假手術(shù)組、模型組、依達(dá)拉奉組、疏血通組、依達(dá)拉奉聯(lián)合疏血通組,采用線栓法復(fù)制大鼠左側(cè)大腦中動(dòng)脈腦缺血(middle cerebral artery occlusion,MCAO)模型,除假手術(shù)組外,每組按不同時(shí)間點(diǎn)(1、3、5、7d)分為4個(gè)亞組,術(shù)后各組腹腔注射相應(yīng)藥物,1次/d,連續(xù)給藥1、3、5、7d,模型組、假手術(shù)組分別予以等體積0.9%氯化鈉溶液,觀察比較各組大鼠神經(jīng)功能缺損評分、腦組織梗死體積、腦組織含水量、腦組織形態(tài)學(xué)改變及白細(xì)胞計(jì)數(shù)(WBC)、谷丙轉(zhuǎn)氨酶(ALT)、谷草轉(zhuǎn)氨酶(AST)、肌酐(Cr)、尿素氮(BUN)、磷酸肌酸激酶(CK)、乳酸脫氫酶(LDH)、活化部分凝血活酶時(shí)間(APTT)等變化。結(jié)果:與假手術(shù)組比較,其余各組神經(jīng)功能缺損評分、腦組織含水量、腦梗死體積均顯著增高(P0.05,P0.01);與模型組比較,各用藥組的神經(jīng)功能缺損評分、腦組織含水量、腦梗死體積和安全性評價(jià)指標(biāo)(WBC、AST、APTT)均有不同程度降低(P0.05,P0.01);與依達(dá)拉奉組、疏血通組比較,聯(lián)合用藥組的神經(jīng)功能缺損評分、腦組織含水量、腦梗死體積減少更明顯(P0.05,P0.01),安全性指標(biāo)差異無統(tǒng)計(jì)學(xué)意義。結(jié)論:依達(dá)拉奉聯(lián)合疏血通在改善大鼠神經(jīng)功能缺損癥狀、減少腦梗死體積、減輕腦水腫3個(gè)方面均優(yōu)于依達(dá)拉奉組、疏血通組,且不良反應(yīng)發(fā)生率低,安全性較好。
[Abstract]:Objective: to evaluate the efficacy and safety of Edaravone combined with Shuxuetong injection in the treatment of acute cerebral infarction rats. Methods: SD rats were randomly divided into three groups: sham operation group, model group, Edaravone group, Shuxuetong group, Edaravone combined with Shuxuetong group. The left middle cerebral artery (MCAO) was induced by (middle cerebral artery occlusion. Each group was divided into 4 subgroups according to different time points (1: 3, 5? 5? 7 days). Each group received intraperitoneal injection of the corresponding drug once a day for 7 days. The model group and sham operation group were given 0.9% sodium chloride solution of the same volume, respectively. The neurological impairment scores of each group were observed and compared. The changes of infarct volume, water content of brain tissue, morphology of brain tissue, WBC, alt, AST, Cr, bun, CK, LDH, APTT, etc. Results: compared with the sham operation group, the scores of nerve function defect, the water content of brain tissue and the volume of cerebral infarction were significantly increased in the other groups (P0.05, P0.01), and compared with the model group, the neurological function defect score and the water content of brain tissue in the other groups were significantly higher than those in the model group. Compared with Edaravone group and Shuxuetong group, compared with Edaravone group and Shuxuetong group, the neurological deficit score and water content of brain tissue in combined treatment group were lower than those in Edaravone group and Shuxuetong group. Cerebral infarction volume decreased more significantly (P 0.05 P 0.01), there was no significant difference in safety index. Conclusion: Edaravone combined with Shuxuetong is superior to Edaravone group and Shuxuetong group in improving neurological deficit symptoms, reducing cerebral infarction volume and alleviating cerebral edema.
【作者單位】： 湖南中醫(yī)藥大學(xué)第一附屬醫(yī)院;湖南中醫(yī)藥大學(xué);
【基金】：湖南省科技廳重點(diǎn)項(xiàng)目(No.2014SK2007)~~
【分類號】：R743.3

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 申銀玲;;疏血通注射液治療短暫性腦缺血發(fā)作臨床觀察[J];中國社區(qū)醫(yī)師(醫(yī)學(xué)專業(yè));2012年18期

2 黎明全;謝雁鳴;趙建軍;;疏血通注射液聯(lián)合靜脈用藥在急性腦梗死治療中的合理安全應(yīng)用[J];中國中藥雜志;2012年18期

3 郭錫池;許曉玲;;疏血通注射液聯(lián)合鹽酸氟桂利嗪膠囊治療椎-基底動(dòng)脈供血不足性眩暈55例療效觀察[J];中國醫(yī)學(xué)前沿雜志(電子版);2014年05期

4 董華麗;;疏血通注射液治療特發(fā)性面神經(jīng)麻痹療效觀察[J];中國實(shí)用神經(jīng)疾病雜志;2013年14期

5 岳正彬;;疏血通注射液治療腦梗塞療效觀察[J];大家健康(學(xué)術(shù)版);2014年07期

6 李娟;桑文翔;;疏血通注射液治療急性腦梗死90例臨床觀察[J];中國現(xiàn)代醫(yī)生;2010年30期

7 李煒;劉曉梅;張燕;王博巖;;疏血通注射液治療腦梗死的臨床療效觀察[J];實(shí)用心腦肺血管病雜志;2014年09期

8 黃少文;;疏血通注射液治療急性缺血性腦血管病的臨床療效分析[J];大家健康(學(xué)術(shù)版);2012年22期

9 廉全榮;封臻;;疏血通注射液配合西藥治療急性腦梗死療效觀察[J];陜西中醫(yī);2014年03期

10 呂瑾;;疏血通注射液對急性缺血性腦卒中患者神經(jīng)功能及血液流變學(xué)的影響[J];大家健康(學(xué)術(shù)版);2013年19期

相關(guān)會(huì)議論文 前1條

1 吳明華;姜亞軍;常誠;王永生;李如英;;疏血通注射液治療急性腔隙性腦梗死64例的臨床療效觀察[A];中華醫(yī)學(xué)會(huì)第七次全國神經(jīng)病學(xué)學(xué)術(shù)會(huì)議論文匯編[C];2004年

，

本文編號：2075148